Clinical trials: Hyperaldosteronism
Prostate Cancer
Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy
The purpose of the study is to determine the safety and clinical benefit of the combinations of abiraterone acetate and prednisone or abiraterone and dexamethasone in prostate cancer patients.
- Trial name
- NCT01867710
- Testing
- Abiraterone Acetate, Prednisone 5 mg twice daily, Prednisone 5 mg once daily
- Where
- 17 sites in Belgium, Germany and 2 more
- Volunteers
- 164 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Primary Aldosteronism
A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism
This study is a multicenter, randomized, double-blind, placebo-parallel-controlled phase II clinical trial to evaluate the efficacy and safety of HRS-1780 compared with placebo in participants with primary aldosteronism.
- Trial name
- NCT07470983
- Testing
- HRS-1780 Tablets
- Where
- 2 sites in China
- Volunteers
- 61 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Primary Hyperaldosteronism
Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.
Parent study: This is a Phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of baxdrostat versus placebo, on the reduction of Seated Blood…
- Trial name
- BaxPA (NCT07007793)
- Testing
- Baxdrostat
- Where
- 76 sites in United States, Australia and 10 more
- Volunteers
- 212 people
- Sponsor
- AstraZeneca
Mild Cognitive Impairment (MCI)
Nutritional Intervention With the Dietary Supplement, Immunocal® in MCI Patients: Promotion of Brain Health
Alzheimer disease (AD) is a dementing illness characterized by progressive neuronal degeneration, gliosis, and the accumulation of intracellular inclusions and extracellular deposits of amyloid in discrete regions of the basal…
- Trial name
- NCT03448055
- Testing
- Immunocal
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- Immunotec Inc.
Primary Aldosteronism
Study of QLS1410 in the Treatment of Primary Aldosteronism.
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of QLS1410 versus placebo, on the reduction of Seated Blood Pressure (SBP) in…
- Trial name
- NCT07550465
- Testing
- QLS1410
- Volunteers
- 60 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Primary Aldosteronism, Hyperaldosteronism
A Study of CIN-107 in Adults With Primary Aldosteronism
This is a multicenter, open-label study in adult patients with PA to evaluate the effectiveness and safety of CIN-107 after up to 12 weeks of treatment (Part 1), and then for eligible, consenting patients follow patients in Part…
- Trial name
- NCT04605549
- Testing
- CIN-107 2 mg dosing, CIN-107 4 mg dosing, CIN-107 8 mg dosing
- Where
- 10 sites in United States
- Volunteers
- 15 people
- Sponsor
- AstraZeneca
Primary Hyperaldosteronism
Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism
The purpose of this study is to determine if LCI699, thorough reductions in aldosterone, can lower BP in patients with Primary hyperaldosteronism.
- Trial name
- NCT00732771
- Testing
- LCI699
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Novartis
Primary Aldosteronism
A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism
This is a multicenter, randomized, double-blind, placebo-controlled phase II study designed to explore the efficacy and safety of different doses of SAL0140 in primary aldosteronism.
- Trial name
- NCT07646535
- Testing
- SAL0140 Tablets
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Primary Aldosteronism
Study of CS-3150 in Patients With Primary Aldosteronism
To examine antihypertensive effect and safety of CS-3150 in patients with primary aldosteronism.
- Trial name
- NCT02885662
- Testing
- CS-3150
- Where
- Japan
- Volunteers
- 44 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Safety and Pharmacokinetics in Healthy Volunteer Subjects
A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects
Part 1: To characterize the biotransformation and excretion of CC-223 following a single 20-mg oral dose of CC-223 capsule containing a microtracer of [14C]-CC-223 solution in healthy male subjects; and to evaluate the…
- Trial name
- AME/FE (NCT01611467)
- Testing
- CC-223
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Celgene
Primary Aldosteronism
DP13 - A Phase II Study in Patients With Primary Aldosteronism
The purpose of the present phase II study is to determine whether DP13 displays the clinical safety and efficacy profile to support further development in patients with primary aldosteronism.
- Trial name
- NCT04007406
- Testing
- dexfadrostat phosphate
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- Damian Pharma AG